The study was set up in order to check the usefulness of peripheral blood eosinophilia in asthma diagnosis and asthma therapy monitoring. Twenty mild asthmatics entered the study--ten atopic and ten nonatopic. Eosinophilia was estimated twice: on the day of admission and twenty four hours after bronchial provocation. Bronchial hyperreactivity was measured on both occasions. We showed, that there was no difference in eosinophilia between atopic and nonatopic subjects before provocation but the difference was significant 24 hrs after provocation. In both groups of asthmatics eosinophilia correlated with bronchial hyperreactivity before and after provocation. We concluded, that eosinophilia is an easy and valuable parameter in monitoring the degree of allergic inflammation in asthmatics.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Spinal schistosomiasis masquerading as spinal cord tumor in a 12-year-old male adolescent: A case report.
Radiol Case Rep
March 2025
School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Spinal schistosomiasis, a rare manifestation of schistosomal infection, can closely mimic the presentation of spinal cord tumors and pose significant diagnostic challenges. We present the case of a 12-year-old boy from northern Ethiopia who experienced progressive back pain, tingling sensations in his lower extremities, and intermittent fever. Initially referred with a presumptive diagnosis of myxopapillary ependymoma for pediatric hematology-oncology evaluation, his marked eosinophilia and history of swimming in local rivers raised suspicion for spinal schistosomiasis.
View Article and Find Full Text PDFIntroduction: Benralizumab is an interleukin 5-receptor-blocking drug registered for the treatment of eosinophilic asthma. It has proven efficient and safe in a small phase-II trial in hypereosinophilic syndrome and is currently being investigated in a larger, randomized phase-III trial. We report on real-world experience with benralizumab in 15 patients with severe Hypereosinophilic syndrome (HES) that were refractory to other treatments or on unacceptable steroid doses.
View Article and Find Full Text PDFA variety of clinical presentations of eosinophilic granulomatosis with polyangiitis: a comprehensive review.
Reumatologia
December 2024
Department of Rheumatology and Immunology, Jagiellonian University Medical College, Krakow, Poland.
Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by eosinophilic granulomatous vasculitis. Typical symptoms include late-onset bronchial asthma and blood and tissue eosinophilia. In addition to these characteristic symptoms, EGPA can affect important organs such as the skin, kidneys, heart, sinuses, gastrointestinal tract, and nervous system.
View Article and Find Full Text PDF[Status of pathological diagnosis of eosinophilic gastroenteritis].
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Symptomatic Improvement in Adults and Adolescents With Eosinophilic Esophagitis Requires Higher Systemic Dupilumab Exposure Than Histologic Response.
Clin Transl Gastroenterol
January 2025
Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
Introduction: We assessed potential mechanisms behind the requirement for more frequent dupilumab dosing in eosinophilic esophagitis (EoE) compared with other approved indications.
Methods: Results for the phase 3 LIBERTY EoE TREET study coprimary endpoints (proportion of patients achieving a peak intraepithelial eosinophil count of ≤6 eosinophils per high-power field and absolute change from baseline in Dysphagia Symptom Questionnaire total score) were pooled in exposure-response analyses.
Results: A steep initial relationship then plateau was observed between higher dupilumab steady-state trough concentrations and decreased eosinophilic infiltration at week 24, whereas a graded exposure-response relationship was observed for symptomatic improvement at week 24.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!